Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Henke

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
World Journal of Gastroenterology|April 13, 2006
Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (1989-2002)Christian Weissenberger, Michael Geissler, Florian Otto, et al.
Stem Cells (Dayton, Ohio)|June 23, 2009
Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trialChris P Miller, Kimberly A Lowe, Karine Valliant-Saunders, et al.
Development (Cambridge, England)|July 31, 2009
Neurog2 is a direct downstream target of the Ptf1a-Rbpj transcription complex in dorsal spinal cordR Michael Henke, Trisha K Savage, David M Meredith, et al.
Frontiers in Oncology|October 13, 2025
Increased acid sphingomyelinase levels in saliva as oral mucositis severity predictorsElsa Beatriz Monroy Ordonez, Tanja Sprave, Andreas R Thomsen, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|May 5, 2006
Religious belief as a coping strategy: an explorative trial in patients irradiated for head-and-neck cancerGerhild Becker, Felix Momm, Carola Xander, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2011
Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trialMichael Henke, Marc Alfonsi, Paolo Foa, et al.
Clinical and Translational Radiation Oncology|February 3, 2025
Evaluating the radiosensitivity of the oral microbiome to predict radiation-induced mucositis in head and neck cancer patients: A prospective trialAndreas R Thomsen, Elsa Beatriz Monroy Ordonez, Michael Henke, et al.
Lancet (London, England)|October 25, 2003
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trialMichael Henke, Roland Laszig, Christian Rübe, et al.
Annals of Botany|August 23, 2011
Towards a functional-structural plant model of cut-rose: simulation of light environment, light absorption, photosynthesis and interference with the plant structureGerhard Buck-Sorlin, Pieter H B de Visser, Michael Henke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology GroupDanny Rischin, Lester J Peters, Brian O'Sullivan, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
World Journal of Gastroenterology|April 13, 2006
Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (1989-2002)Christian Weissenberger, Michael Geissler, Florian Otto, et al.
Stem Cells (Dayton, Ohio)|June 23, 2009
Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trialChris P Miller, Kimberly A Lowe, Karine Valliant-Saunders, et al.
Development (Cambridge, England)|July 31, 2009
Neurog2 is a direct downstream target of the Ptf1a-Rbpj transcription complex in dorsal spinal cordR Michael Henke, Trisha K Savage, David M Meredith, et al.
Frontiers in Oncology|October 13, 2025
Increased acid sphingomyelinase levels in saliva as oral mucositis severity predictorsElsa Beatriz Monroy Ordonez, Tanja Sprave, Andreas R Thomsen, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|May 5, 2006
Religious belief as a coping strategy: an explorative trial in patients irradiated for head-and-neck cancerGerhild Becker, Felix Momm, Carola Xander, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2011
Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trialMichael Henke, Marc Alfonsi, Paolo Foa, et al.
Clinical and Translational Radiation Oncology|February 3, 2025
Evaluating the radiosensitivity of the oral microbiome to predict radiation-induced mucositis in head and neck cancer patients: A prospective trialAndreas R Thomsen, Elsa Beatriz Monroy Ordonez, Michael Henke, et al.
Lancet (London, England)|October 25, 2003
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trialMichael Henke, Roland Laszig, Christian Rübe, et al.
Annals of Botany|August 23, 2011
Towards a functional-structural plant model of cut-rose: simulation of light environment, light absorption, photosynthesis and interference with the plant structureGerhard Buck-Sorlin, Pieter H B de Visser, Michael Henke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology GroupDanny Rischin, Lester J Peters, Brian O'Sullivan, et al.
Pageof 8